Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.09
TMO's Cash to Debt is ranked lower than
55% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. TMO: 0.09 )
TMO' s 10-Year Cash to Debt Range
Min: 0.09   Max: 2.13
Current: 0.09

0.09
2.13
Equity to Asset 0.48
TMO's Equity to Asset is ranked higher than
60% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. TMO: 0.48 )
TMO' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.75
Current: 0.48

0.35
0.75
Interest Coverage 5.22
TMO's Interest Coverage is ranked lower than
51% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. TMO: 5.22 )
TMO' s 10-Year Interest Coverage Range
Min: 3.21   Max: 21.63
Current: 5.22

3.21
21.63
F-Score: 7
Z-Score: 2.35
M-Score: -2.28
WACC vs ROIC
8.28%
6.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.51
TMO's Operating margin (%) is ranked higher than
89% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. TMO: 12.51 )
TMO' s 10-Year Operating margin (%) Range
Min: 1.56   Max: 14.82
Current: 12.51

1.56
14.82
Net-margin (%) 10.27
TMO's Net-margin (%) is ranked higher than
90% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. TMO: 10.27 )
TMO' s 10-Year Net-margin (%) Range
Min: -7.07   Max: 16.75
Current: 10.27

-7.07
16.75
ROE (%) 8.51
TMO's ROE (%) is ranked higher than
83% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.68 vs. TMO: 8.51 )
TMO' s 10-Year ROE (%) Range
Min: -8.18   Max: 15.73
Current: 8.51

-8.18
15.73
ROA (%) 3.99
TMO's ROA (%) is ranked higher than
84% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. TMO: 3.99 )
TMO' s 10-Year ROA (%) Range
Min: -3.29   Max: 10.39
Current: 3.99

-3.29
10.39
ROC (Joel Greenblatt) (%) 50.34
TMO's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. TMO: 50.34 )
TMO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.07   Max: 61.38
Current: 50.34

4.07
61.38
Revenue Growth (3Y)(%) 11.80
TMO's Revenue Growth (3Y)(%) is ranked higher than
88% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. TMO: 11.80 )
TMO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -12.9   Max: 18.7
Current: 11.8

-12.9
18.7
EBITDA Growth (3Y)(%) 23.40
TMO's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. TMO: 23.40 )
TMO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30   Max: 40.8
Current: 23.4

-30
40.8
EPS Growth (3Y)(%) 21.00
TMO's EPS Growth (3Y)(%) is ranked higher than
91% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. TMO: 21.00 )
TMO' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.3   Max: 74.6
Current: 21

-41.3
74.6
» TMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TMO Guru Trades in Q2 2014

Eric Mindich 432,000 sh (New)
Ruane Cunniff 3,101 sh (+21.56%)
Larry Robbins 10,942,193 sh (+14.45%)
PRIMECAP Management 3,962,230 sh (+11.24%)
Leon Cooperman 898,800 sh (+6.02%)
Pioneer Investments 1,923,572 sh (+3.93%)
First Pacific Advisors 3,521,200 sh (+0.34%)
Jean-Marie Eveillard 200 sh (unchged)
Steven Romick 3,315,000 sh (unchged)
Steven Cohen 148,400 sh (unchged)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
Jeremy Grantham Sold Out
John Rogers 536,928 sh (-3.45%)
Bill Frels 1,785 sh (-6.54%)
Dodge & Cox 81,002 sh (-6.57%)
John Griffin 2,715,000 sh (-7.18%)
Andreas Halvorsen 8,271,280 sh (-14.45%)
Scott Black 79,652 sh (-28.03%)
John Paulson 3,225,000 sh (-29.20%)
Paul Tudor Jones 6,390 sh (-30.05%)
David Dreman 16,420 sh (-30.09%)
» More
Q3 2014

TMO Guru Trades in Q3 2014

Joel Greenblatt 3,314 sh (New)
Vanguard Health Care Fund 1,494,300 sh (New)
Jim Simons 37,844 sh (New)
Caxton Associates 45,000 sh (New)
Eric Mindich 1,119,000 sh (+159.03%)
Signature Select Canadian Fund 122,600 sh (+38.06%)
Bill Frels 2,381 sh (+33.39%)
PRIMECAP Management 4,308,150 sh (+8.73%)
Larry Robbins 11,375,667 sh (+3.96%)
First Pacific Advisors 3,549,700 sh (+0.81%)
John Rogers 540,702 sh (+0.70%)
Ruane Cunniff 3,101 sh (unchged)
Pioneer Investments 1,985,531 sh (unchged)
John Griffin 2,715,000 sh (unchged)
Steven Romick 3,315,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
John Paulson Sold Out
Scott Black 79,249 sh (-0.51%)
David Dreman 16,213 sh (-1.26%)
Andreas Halvorsen 7,976,502 sh (-3.56%)
Leon Cooperman 864,000 sh (-3.87%)
Dodge & Cox 57,082 sh (-29.53%)
Steven Cohen 79,800 sh (-46.23%)
Paul Tudor Jones 3,200 sh (-49.92%)
» More
Q4 2014

TMO Guru Trades in Q4 2014

Mario Gabelli 13,000 sh (New)
Ray Dalio 11,899 sh (New)
Jim Simons 206,644 sh (+446.04%)
Steven Cohen 239,700 sh (+200.38%)
Paul Tudor Jones 4,763 sh (+48.84%)
Vanguard Health Care Fund 2,179,000 sh (+45.82%)
Eric Mindich 1,563,000 sh (+39.68%)
John Rogers 580,501 sh (+7.36%)
PRIMECAP Management 4,487,090 sh (+4.15%)
Bill Frels 2,446 sh (+2.73%)
Steven Romick 3,381,300 sh (+2.00%)
First Pacific Advisors 3,617,400 sh (+1.91%)
Larry Robbins 11,387,265 sh (+0.10%)
Jean-Marie Eveillard 200 sh (unchged)
Caxton Associates Sold Out
Joel Greenblatt Sold Out
Leon Cooperman Sold Out
Pioneer Investments 1,965,136 sh (-1.03%)
David Dreman 15,984 sh (-1.41%)
Dodge & Cox 56,202 sh (-1.54%)
Scott Black 74,862 sh (-5.54%)
Ruane Cunniff 2,873 sh (-7.35%)
John Griffin 2,115,000 sh (-22.10%)
Andreas Halvorsen 5,786,510 sh (-27.46%)
» More
Q1 2015

TMO Guru Trades in Q1 2015

Steven Romick 3,180,000 sh (-5.95%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Thermo Fisher Scientific Inc

John Rogers Comments on Thermo Fisher Scientific Inc. - May 07, 2014

In addition, scientific research specialist Thermo Fisher Scientific Inc. (TMO) returned +8.12% after a very solid earnings report. Its revenue was $3.5 billion, up 6% over the previous period, and its earnings per share was $1.43, significantly above the $1.37 cons ensus estimate. Its forecast for 2014 was even more positive : full-year revenue guidance was in the $16 billion-plus ra nge, smashing the $13 billion consensus estimate, and the low end of its EPS guidance was more than $0.40 higher than Wall Street's best guess. Our strategy with Thermo Fisher has been to look beyond the gloom and doom that has cast a dark cloud over the whole sector to see the potential for a bright future.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Thermo Fisher Scientific Inc

John Rogers Comments on Thermo Fisher Scientific Inc.
In addition, scientific research specialist Thermo Fisher Scientific Inc. (TMO) returned +8.12% after a very solid earnings report. Its revenue was $3.5 billion, up 6% over the previous period, and its earnings per share was $1.43, significantly above the $1.37 cons ensus estimate. Its forecast for 2014 was even more positive : full-year revenue guidance was in the $16 billion-plus ra nge, smashing the $13 billion consensus estimate, and the low end of its EPS guidance was more than $0.40 higher than Wall Street's best guess. Our strategy with Thermo Fisher has been to look beyond the gloom and doom that has cast a dark cloud over the whole sector to see the potential for a bright future. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.60
TMO's P/E(ttm) is ranked higher than
88% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 27.60 )
TMO' s 10-Year P/E(ttm) Range
Min: 11.11   Max: 55.16
Current: 27.6

11.11
55.16
Forward P/E 15.85
TMO's Forward P/E is ranked higher than
93% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 15.85 )
N/A
PE(NRI) 27.60
TMO's PE(NRI) is ranked higher than
91% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 27.60 )
TMO' s 10-Year PE(NRI) Range
Min: 13.48   Max: 54.55
Current: 27.6

13.48
54.55
P/B 2.60
TMO's P/B is ranked higher than
78% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. TMO: 2.60 )
TMO' s 10-Year P/B Range
Min: 0.5   Max: 2.67
Current: 2.6

0.5
2.67
P/S 3.10
TMO's P/S is ranked higher than
64% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.43 vs. TMO: 3.10 )
TMO' s 10-Year P/S Range
Min: 1.24   Max: 3.48
Current: 3.1

1.24
3.48
PFCF 23.90
TMO's PFCF is ranked higher than
88% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 23.90 )
TMO' s 10-Year PFCF Range
Min: 10.22   Max: 32.28
Current: 23.9

10.22
32.28
POCF 19.99
TMO's POCF is ranked higher than
87% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 19.99 )
TMO' s 10-Year POCF Range
Min: 8.72   Max: 26.55
Current: 19.99

8.72
26.55
EV-to-EBIT 25.82
TMO's EV-to-EBIT is ranked higher than
83% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 25.82 )
TMO' s 10-Year EV-to-EBIT Range
Min: 11.2   Max: 73.5
Current: 25.82

11.2
73.5
PEG 1.52
TMO's PEG is ranked higher than
97% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 1.52 )
TMO' s 10-Year PEG Range
Min: 0.56   Max: 11.39
Current: 1.52

0.56
11.39
Shiller P/E 39.20
TMO's Shiller P/E is ranked higher than
87% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 39.20 )
TMO' s 10-Year Shiller P/E Range
Min: 17.09   Max: 66.69
Current: 39.2

17.09
66.69
Current Ratio 1.22
TMO's Current Ratio is ranked higher than
53% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. TMO: 1.22 )
TMO' s 10-Year Current Ratio Range
Min: 1.22   Max: 3.83
Current: 1.22

1.22
3.83
Quick Ratio 0.87
TMO's Quick Ratio is ranked higher than
51% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. TMO: 0.87 )
TMO' s 10-Year Quick Ratio Range
Min: 0.87   Max: 3.4
Current: 0.87

0.87
3.4
Days Inventory 77.52
TMO's Days Inventory is ranked higher than
80% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.68 vs. TMO: 77.52 )
TMO' s 10-Year Days Inventory Range
Min: 65.13   Max: 183.33
Current: 77.52

65.13
183.33
Days Sales Outstanding 54.80
TMO's Days Sales Outstanding is ranked higher than
83% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. TMO: 54.80 )
TMO' s 10-Year Days Sales Outstanding Range
Min: 50.89   Max: 159.82
Current: 54.8

50.89
159.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.46
TMO's Dividend Yield is ranked lower than
84% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. TMO: 0.46 )
TMO' s 10-Year Dividend Yield Range
Min: 0.22   Max: 0.86
Current: 0.46

0.22
0.86
Dividend Payout 0.13
TMO's Dividend Payout is ranked higher than
99% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 0.13 )
TMO' s 10-Year Dividend Payout Range
Min: 0.13   Max: 0.17
Current: 0.13

0.13
0.17
Yield on cost (5-Year) 0.50
TMO's Yield on cost (5-Year) is ranked lower than
78% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. TMO: 0.50 )
TMO' s 10-Year Yield on cost (5-Year) Range
Min: 0.22   Max: 0.86
Current: 0.5

0.22
0.86
Share Buyback Rate -1.50
TMO's Share Buyback Rate is ranked higher than
77% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. TMO: -1.50 )
TMO' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -38.3
Current: -1.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.30
TMO's Price/DCF (Projected) is ranked higher than
94% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 1.30 )
TMO' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 14.42
Current: 1.3

0.6
14.42
Price/Median PS Value 1.40
TMO's Price/Median PS Value is ranked higher than
66% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. TMO: 1.40 )
TMO' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 1.43
Current: 1.4

0.38
1.43
Price/Peter Lynch Fair Value 1.50
TMO's Price/Peter Lynch Fair Value is ranked higher than
98% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TMO: 1.50 )
TMO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.63   Max: 2.42
Current: 1.5

0.63
2.42
Earnings Yield (Greenblatt) 3.90
TMO's Earnings Yield (Greenblatt) is ranked higher than
80% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. TMO: 3.90 )
TMO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 8.9
Current: 3.9

1.4
8.9
Forward Rate of Return (Yacktman) 21.63
TMO's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. TMO: 21.63 )
TMO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.2   Max: 34.8
Current: 21.63

-19.2
34.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, COO, ISRG » details
Traded in other countries:TN8.Germany, TMO.Mexico,
Thermo Fisher Scientific Inc is a Delaware corporation and was incorporated in 1956. The Company completed its initial public offering in 1967 and was listed on the New York Stock Exchange in 1980. In November 2006, Thermo Electron Corporation merged with Fisher Scientific International Inc. to create Thermo Fisher. The Company completed its initial public offering in 1967. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It serves more than 400,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. The Company's continuing operations fall into three business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Analytical Technologies segment provides offerings of instruments, reagents, consumables, software and services that are used for applications in the laboratory, on the production line and in the field. These products are used by customers in all four of the company's key end markets: healthcare and diagnostics; pharmaceutical and biotechnology; academic and government; and industrial and applied. This segment includes four primary businesses - Chromatography and Mass Spectrometry, Chemical Analysis, Environmental and Process Instruments, and Biosciences. Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. Its chemical analysis products fall into three main categories: materials and minerals; molecular spectroscopy; and portable analytical instruments. Customers use these products to quickly and accurately analyze the composition of materials in small samples to optimize workflows in academic, life sciences, pharmaceutical, and industrial applications. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services segment provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The Company serves their customers through four brands, Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services. The Company markets and sells its products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs. It encounters aggressive and able competition in virtually all of the markets it serves. It is subject to
» More Articles for TMO

Headlines

Articles On GuruFocus.com
Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
The Gurus to Follow Based on Sector — Part 2 Dec 09 2014 
Glenview's Larry Robbins Adds to Stake in Watchmaker Fossil Sep 15 2014 
John Rogers Comments on Thermo Fisher Scientific Inc. May 07 2014 
John Rogers' Ariel Appreciation Fund First Quarter 2014 Commentary Apr 30 2014 
Steven Romick's Top Five Highlight Technology Sector Apr 16 2014 
Different Opinions on Bio-Rad Laboratories Apr 03 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
Steven Romick’s Top Five Q4 Holdings Jan 14 2014 

More From Other Websites
Thermo Fisher Scientific (TMO) Earnings Analysis: By the Numbers Apr 24 2015
Thermo Fisher Scientific (TMO) Earnings Report: Q1 2015 Conference Call Transcript Apr 22 2015
Thermo Fisher Q1 Earnings Top, Revenues Lag Estimates - Analyst Blog Apr 22 2015
What We’re Trading Apr 22 2015
Early movers: BA, KO, TMO, NLSN, AN & more Apr 22 2015
Thermo Fisher Beats on Q1 Earnings, Misses Revenues - Tale of the Tape Apr 22 2015
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 22 2015
Q1 2015 Thermo Fisher Scientific Inc Earnings Release - Before Market Open Apr 22 2015
Thermo Fisher Sees Lower 2015 Sales Apr 22 2015
Thermo Fisher Scientific Reports First Quarter 2015 Results Apr 22 2015
Thermo Fisher tops 1Q profit forecasts Apr 22 2015
Thermo Fisher tops 1Q profit forecasts Apr 22 2015
Thermo Fisher Scientific Reports First Quarter 2015 Results Apr 22 2015
Thermo Fisher trims 2015 revenue outlook, citing strong dollar Apr 22 2015
Will Thermo Fisher's (TMO) Q1 Earnings Surprise Investors? - Analyst Blog Apr 21 2015
New Blast Freezers Offer Rapid Freezing of Critical Bioprocessing Samples Apr 21 2015
New Innovations in Upstream and Downstream Bioprocessing on Display at Interphex 2015 Apr 21 2015
Thermo Fisher Scientific Announces Next-Generation Sequencing Oncomine Focus Assay for Oncology... Apr 20 2015
Horizon & Thermo Fisher Scientific Sign Agreement Apr 20 2015
Horizon Discovery Group plc and Thermo Fisher Scientific Sign Supply and Commercialisation Agreement Apr 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK